share_log

港股异动 | 再鼎医药(09688)涨超5% 与辉瑞就新型抗菌药物鼎优乐达成在中国内地合作

Hong Kong stocks fluctuate | Zai Lab (09688) rises over 5% as it cooperates with Pfizer on the new antibacterial drug in mainland China.

Zhitong Finance ·  Nov 24, 2024 17:41

Zaiding Pharmaceuticals (09688) rose more than 5%. As of press release, it rose 5.26% to HK$20.8, with a turnover of HK$7.8692 million.

The Zhitong Finance App learned that Zaiding Pharmaceutical (09688) rose by more than 5%. As of press release, it had risen 5.26% to HK$20.8, with a turnover of HK$7.8692 million.

According to the news, on November 21, Pfizer and Zaiding Pharmaceuticals announced that the two sides have reached a strategic cooperation on the novel antimicrobial drug Dingyule (sulbactam sodium-dulobactan sodium) in mainland China. Pfizer's company is solely responsible for the commercial operation of this product in mainland China. The novel antimicrobial drug Dingyule is currently the only antimicrobial drug specially developed to treat acinetobacter baumannii (CRAB), which is resistant to carbapenems. The product was approved in the US and mainland China in 2023 and 2024, respectively.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment